Study of new drug efficacy index and usefulness of enoxaparin sodium in patients with esophageal cancer

Study of new drug efficacy index and usefulness of enoxaparin sodium in patients with esophageal cancer - Usefulness of Clexane administration of esophageal cancer perioperative

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014623

Enrollment

100

Registered

2014-07-23

Start date

2014-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

enoxaparin sodium none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Esophageal cancer patients to be performed abdominal surgery

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to heparin derivative (1) or heparin (Bleeding, such as intracranial hemorrhage, retroperitoneal bleeding, in other vital organs) patients who have (2) bleeding (3) acute endocarditis patients Renal failure (4) severe (creatinine clearance less than 30mL/min) Patients with a history (5) heparin-induced thrombocytopenia (HIT) (6) Other, patients attending physician was deemed inappropriate for participation in this study

Design outcomes

Primary

Measure	Time frame
Evaluation of leg vein thrombosis, D-dimer, fibrin monomer complex (FMC), the anti-factor Xa activity	—

Countries

Japan

Contacts

Public ContactYoshihito Tanaka

Gifu University Surgical Oncology

yoshihirotana11@hotmail.com0582306000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026